Compare Symbotic Inc (SYM) vs 22nd Century Group Inc (XXII) Price & Performance

SYM trades at $41.19, up 2.69% with bearish technical signals despite recent earnings misses. The company shows revenue growth potential with 2026 projections of $2.6B revenue and positive net income, but current profitability remains weak with negative EBITDA and slim 0.31% net margin. Recent Q3 2026 earnings missed expectations despite 21.7% revenue growth, causing a 10.3% stock drop according to Defense World on August 7, 2026.

Analyst consensus remains bullish with a $60 price target (61.11% buy ratings), but execution risks persist amid margin pressure and competitive threats. The stock faces near-term headwinds from consecutive earnings misses while long-term robotics automation trends provide growth catalysts. Current valuation metrics show elevated P/E of 1,042.25 and EV/EBITDA of 73.09, requiring significant earnings acceleration to justify.

XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.

The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.